Completed
Multicenter Trial of Prednisone in Alzheimers Disease
Led by National Institute on Aging (NIA) · Updated on 2005-06-24
N/A
Participants Needed
19
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a randomized placebo controlled, double blind study. Patients who meet eligibility criteria and decide to participate in the study will be randomly assigned to receive either drug treatment or a placebo. Neither the patients nor the participating investigators will know who is receiving the drugs and who is receiving the placebo. Participation involves 15 outpatient clinic visits over a 68 week period. Patients take study medication at varying doses (the maximum dose is 20 mg daily), along with calcium and vitamin supplements.
CONDITIONS
Brief Title
Multicenter Trial of Prednisone in Alzheimer's Disease
Who Can Participate
Eligibility Criteria
Inclusion Criteria:
- Patients with Alzheimer's disease who are in stable medical condition
Exclusion Criteria:
- Patients with diabetes or severe osteoporosis
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here